
## **Tobias Walbert**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7500449/publications.pdf Version: 2024-02-01



TORIAS WAIREDT

#	Article	IF	CITATIONS
1	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
2	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	12.4	158
3	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-Oncology, 2018, 20, 1383-1392.	1.2	135
4	Health-related quality of life in patients with narcolepsy. Sleep Medicine, 2007, 8, 733-741.	1.6	134
5	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemotherapy and Pharmacology, 2017, 80, 1209-1217.	2.3	108
6	End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. Journal of Neuro-Oncology, 2014, 117, 217-224.	2.9	93
7	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with <i>EGFR</i> -amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro-Oncology, 2019, 21, 106-114.	1.2	84
8	Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. JAMA Oncology, 2020, 6, 1939.	7.1	84
9	The Socioeconomic Impact of Narcolepsy. Sleep, 2004, 27, 1123-1128.	1.1	77
10	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro-Oncology, 2021, 23, 1835-1844.	1.2	64
11	The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. International Journal of Clinical Oncology, 2009, 14, 299-306.	2.2	56
12	A serum-based DNA methylation assay provides accurate detection of glioma. Neuro-Oncology, 2021, 23, 1494-1508.	1.2	53
13	Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathologica, 2012, 124, 449-451.	7.7	50
14	Brain metastasis: clinical manifestations, symptom management, and palliative care. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 75-88.	1.8	45
15	The role of tumor board conferences in neuro-oncology: a nationwide provider survey. Journal of Neuro-Oncology, 2017, 133, 1-7.	2.9	43
16	Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey. Journal of Neuro-Oncology, 2016, 126, 337-345.	2.9	41
17	Palliative and Supportive Care for Glioma Patients. Cancer Treatment and Research, 2015, 163, 171-184.	0.5	41
18	Integration of palliative care into the neuro-oncology practice: patterns in the United States. Neuro-Oncology Practice, 2014, 1, 3-7.	1.6	40

TOBIAS WALBERT

#	Article	IF	CITATIONS
19	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro-Oncology, 2017, 19, 845-852.	1.2	39
20	The Impact of Accreditation Council for Graduate Medical Education Duty Hours, the July Phenomenon, and Hospital Teaching Status on Stroke Outcomes. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 232-238.	1.6	33
21	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet Oncology, The, 2018, 19, e173-e180.	10.7	32
22	The safety of magnetic resonance imaging-guided laser interstitial thermal therapy for cerebral radiation necrosis. Journal of Neuro-Oncology, 2018, 138, 609-617.	2.9	32
23	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-Oncology, 2020, 22, 1505-1515.	1.2	27
24	Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. Journal of Neuro-Oncology, 2011, 102, 273-280.	2.9	26
25	Systematic Assessment of Decision Models in Parkinson's Disease. Value in Health, 2004, 7, 610-626.	0.3	23
26	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	1.2	23
27	Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i> -mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro-Oncology, 2023, 25, 146-156.	1.2	23
28	End-of-life care in patients with primary malignant brain tumors: early is better. Neuro-Oncology, 2016, 18, 7-8.	1.2	22
29	Cerebral edema induced by laser interstitial thermal therapy and radiotherapy in close succession in patients with brain tumor. Lasers in Surgery and Medicine, 2018, 50, 917-923.	2.1	21
30	Rapid multicontrast brain imaging on a 0.35T MRâ€linac. Medical Physics, 2020, 47, 4064-4076.	3.0	21
31	Symptomatic Neurocutaneous Melanosis and Dandy-Walker Malformation in an Adult. Journal of Clinical Oncology, 2009, 27, 2886-2887.	1.6	20
32	Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Future Oncology, 2010, 6, 287-297.	2.4	20
33	Recurrent high-grade glioma: a diagnostic and therapeutic challenge. Expert Review of Neurotherapeutics, 2011, 11, 509-518.	2.8	20
34	Recent Advances in the Classification and Treatment of Ependymomas. Current Treatment Options in Oncology, 2017, 18, 55.	3.0	20
35	Determining medical decision-making capacity in brain tumor patients: why and how?. Neuro-Oncology Practice, 2020, 7, 599-612.	1.6	19
36	International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. Neuro-Oncology Practice, 2015, 2, 62-69.	1.6	18

TOBIAS WALBERT

#	Article	IF	CITATIONS
37	The economic impact of glioma survivorship. Neurology, 2020, 95, e1575-e1581.	1.1	18
38	Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. Journal of Neuro-Oncology, 2020, 148, 353-361.	2.9	16
39	Through the patient's eyes: the value of a comprehensive brain tumor center. Journal of Neuro-Oncology, 2014, 119, 465-472.	2.9	12
40	Palliative Care, End-of-Life Care, and Advance Care Planning in Neuro-oncology. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1709-1726.	0.8	12
41	Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. Journal of Neuro-Oncology, 2015, 121, 341-348.	2.9	11
42	Health-related quality of life in meningioma. Neuro-Oncology Advances, 2021, 3, vdab089.	0.7	11
43	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. Neuro-Oncology Practice, 2021, 8, 417-425.	1.6	9
44	Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors. Neuro-Oncology, 2022, 24, 1126-1139.	1.2	9
45	Effect of seizure timing on long-term survival in patients with brain tumor. Epilepsy and Behavior, 2020, 111, 107307.	1.7	7
46	Caregiver perceptions of end-of-life care in patients with high-grade glioma. Neuro-Oncology Practice, 2021, 8, 171-178.	1.6	7
47	Top Ten Tips Palliative Care Clinicians Should Know When Caring for Patients with Brain Cancer. Journal of Palliative Medicine, 2020, 23, 415-421.	1.1	6
48	DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features. Neuro-Oncology, 2021, 23, 1292-1303.	1.2	6
49	Maintaining quality of life near the end of life: hospice in neuro-oncology. Neuro-Oncology, 2018, 20, 439-440.	1.2	5
50	Impaired neurocognitive function in glioma patients: from pathophysiology to novel intervention strategies. Current Opinion in Neurology, 2020, 33, 716-722.	3.6	5
51	Neuro-oncology and supportive care: the role of the neurologist. Neurological Sciences, 2022, 43, 939-950.	1.9	5
52	Clinical and research applications of a brain tumor tissue bank in the age of precision medicine. Personalized Medicine, 2019, 16, 145-156.	1.5	4
53	Impact of ACGME Standards Is Yet To Be Determined. American Journal of Medicine, 2008, 121, e21-e22.	1.5	2
54	Simultaneous care in neuro-oncology. Neuro-Oncology, 2018, 20, 302-303.	1.2	2

#	Article	IF	CITATIONS
55	Health-Related Quality of Life Related to Toxicity Treatments in Central Nervous System Metastases. , 2020, , 373-382.		1
56	OUP accepted manuscript. Neuro-Oncology, 2022, , .	1.2	0